N-Acetyl-L-tryptophan (NAT, Ac-Trp-OH) is used a substance P NK1 tachykinin receptor antagonist. N-Acetyl-L-tryptophan is also used as a competitive inhibitor to identify, differentiate and characterized tryptophanase(s).
Journal of neurotrauma, 28(2), 217-224 (2010-12-24)
Previous studies have demonstrated that the compound N-acetyl-L-tryptophan (NAT) reduces brain edema and improves functional outcome following traumatic brain injury (TBI). In this study we examined whether this effect was mediated via the neurokinin-1 receptor, and whether there was an
Journal of chromatography. A, 1218(41), 7316-7324 (2011-09-10)
N-acetyltryptophan (NAT) has long been used as a stabilizer in some protein solutions, such as human serum albumin, to prevent oxidative protein degradation. However, the fate of NAT has not been discussed in literature. Two NAT degradation products have been
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 29(8), 1388-1398 (2009-05-14)
Brain edema and swelling is a critical factor in the high mortality and morbidity associated with traumatic brain injury (TBI). Despite this, the mechanisms associated with its development are poorly understood and interventions have not changed in over 30 years.
New tryptophanase inhibitors: towards prevention of bacterial biofilm formation.
Emend, an NK1 antagonist, and dexamethasone are used to treat complications associated with metastatic brain tumours and their treatment. It has been suggested that these agents exert anticancer effects apart from their current use. The effects of the NK1 antagonists
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
